Insys Therapeutics Company Profile (NASDAQ:INSY)

About Insys Therapeutics (NASDAQ:INSY)

Insys Therapeutics logoInsys Therapeutics, Inc. is a commercial-stage specialty pharmaceutical company. The Company develops and commercializes supportive care products. The Company's product Subsys, is a sublingual fentanyl spray for breakthrough cancer pain (BTCP) in opioid-tolerant patients and a single-use product that delivers fentanyl, an opioid analgesic, for transmucosal absorption underneath the tongue. The Company markets Subsys through its field sales force focused on supportive care physicians in the United States. Subsys delivers a liquid fentanyl formulation in approximately 100, 200, 400, 600, 800, 1,200 and 1,600 micrograms (mcg) dosages. The Company's lead dronabinol product candidate is Syndros, which is under review for approval at the Food and Drug Administration. In addition, the Company is evaluating sublingual spray, inhaled and intravenous formulations of dronabinol in preclinical studies.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Biotechnology
  • Sub-Industry: N/A
  • Symbol: NASDAQ:INSY
  • CUSIP: N/A
  • Web: www.insysrx.com
Capitalization:
  • Market Cap: $967.92 million
  • Outstanding Shares: 72,125,000
Average Prices:
  • 50 Day Moving Avg: $11.27
  • 200 Day Moving Avg: $10.95
  • 52 Week Range: $8.70 - $19.96
P/E:
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: -83.88
  • P/E Growth: -0.98
Sales & Book Value:
  • Annual Revenue: $217.82 million
  • Price / Sales: 4.44
  • Book Value: $3.71 per share
  • Price / Book: 3.62
Profitability:
  • EBIDTA: $3.16 million
  • Net Margins: 8.71%
  • Return on Equity: 9.39%
  • Return on Assets: 7.09%
Debt:
  • Current Ratio: 3.07%
  • Quick Ratio: 2.70%
Misc:
  • Average Volume: 723,982 shs.
  • Beta: 0.26
  • Short Ratio: 13.08
 

Frequently Asked Questions for Insys Therapeutics (NASDAQ:INSY)

What is Insys Therapeutics' stock symbol?

Insys Therapeutics trades on the NASDAQ under the ticker symbol "INSY."

When did Insys Therapeutics' stock split? How did Insys Therapeutics' stock split work?

Insys Therapeutics shares split on Monday, March 31st 2014. The 3-2 split was announced on Tuesday, March 4th 2014. The newly issued shares were distributed to shareholders after the market closes on Friday, March 28th 2014. An investor that had 100 shares of Insys Therapeutics stock prior to the split would have 150 shares after the split.

How were Insys Therapeutics' earnings last quarter?

Insys Therapeutics Inc (NASDAQ:INSY) posted its earnings results on Tuesday, May, 9th. The company reported ($0.09) EPS for the quarter, topping the Zacks' consensus estimate of ($0.10) by $0.01. The firm had revenue of $35.92 million for the quarter, compared to the consensus estimate of $37.78 million. Insys Therapeutics had a return on equity of 9.39% and a net margin of 8.71%. The business's revenue was down 40.5% compared to the same quarter last year. During the same quarter in the previous year, the business earned $0.11 EPS. View Insys Therapeutics' Earnings History.

Where is Insys Therapeutics' stock going? Where will Insys Therapeutics' stock price be in 2017?

4 brokerages have issued 1 year price objectives for Insys Therapeutics' stock. Their forecasts range from $10.00 to $16.00. On average, they anticipate Insys Therapeutics' stock price to reach $13.33 in the next twelve months. View Analyst Ratings for Insys Therapeutics.

Who are some of Insys Therapeutics' key competitors?

Who owns Insys Therapeutics stock?

Insys Therapeutics' stock is owned by a variety of of institutional and retail investors. Top institutional shareholders include Vanguard Group Inc. (3.27%), Dimensional Fund Advisors LP (0.79%), Point72 Asset Management L.P. (0.60%), Credit Agricole S A (0.52%), Geode Capital Management LLC (0.42%) and FMR LLC (0.34%). Company insiders that own Insys Therapeutics stock include Brian Tambi, Daniel Brennan, Fosse Franc Del, John N Kapoor Trust Dated Sept, Patrick Fourteau, Saeed Motahari, Steven J Meyer and Theodore H Stanley. View Institutional Ownership Trends for Insys Therapeutics.

Who sold Insys Therapeutics stock? Who is selling Insys Therapeutics stock?

Insys Therapeutics' stock was sold by a variety of institutional investors in the last quarter, including Bank of New York Mellon Corp, Renaissance Technologies LLC, Vanguard Group Inc., Regal Investment Advisors LLC, FMR LLC, ProShare Advisors LLC, UBS Group AG and Morgan Stanley. Company insiders that have sold Insys Therapeutics stock in the last year include Daniel Brennan, Patrick Fourteau and Theodore H Stanley. View Insider Buying and Selling for Insys Therapeutics.

Who bought Insys Therapeutics stock? Who is buying Insys Therapeutics stock?

Insys Therapeutics' stock was purchased by a variety of institutional investors in the last quarter, including Thrivent Financial For Lutherans, Point72 Asset Management L.P., First Trust Advisors LP, Credit Agricole S A, Bowling Portfolio Management LLC, Cambridge Investment Research Advisors Inc., Geode Capital Management LLC and Weiss Multi Strategy Advisers LLC. Company insiders that have bought Insys Therapeutics stock in the last two years include John N Kapoor Trust Dated Sept, Saeed Motahari and Steven J Meyer. View Insider Buying and Selling for Insys Therapeutics.

How do I buy Insys Therapeutics stock?

Shares of Insys Therapeutics can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

How much does a share of Insys Therapeutics stock cost?

One share of Insys Therapeutics stock can currently be purchased for approximately $13.42.

Analyst Ratings

Consensus Ratings for Insys Therapeutics (NASDAQ:INSY) (?)
Ratings Breakdown: 2 Hold Ratings, 2 Buy Ratings
Consensus Rating:Buy (Score: 2.50)
Consensus Price Target: $13.33 (0.65% downside)

Analysts' Ratings History for Insys Therapeutics (NASDAQ:INSY)
Show:
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
5/10/2017Piper Jaffray CompaniesDowngradeOverweight -> Neutral$20.00 -> $10.00LowView Rating Details
4/28/2017Royal Bank of CanadaReiterated RatingBuy$16.00MediumView Rating Details
4/6/2017Oppenheimer Holdings Inc.Reiterated RatingHoldLowView Rating Details
4/4/2017Jefferies Group LLCLower Price TargetBuy$16.00 -> $14.00LowView Rating Details
4/14/2016Janney Montgomery ScottInitiated CoverageBuy$22.00N/AView Rating Details
3/9/2016JMP SecuritiesLower Price TargetMarket Outperform$38.00 -> $30.00N/AView Rating Details
(Data available from 5/25/2015 forward)

Earnings

Earnings History for Insys Therapeutics (NASDAQ:INSY)
Earnings by Quarter for Insys Therapeutics (NASDAQ:INSY)
Earnings History by Quarter for Insys Therapeutics (NASDAQ:INSY)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
5/9/2017Q1 2017($0.10)($0.09)$37.78 million$35.92 millionViewListenView Earnings Details
4/3/2017Q4 2016$0.00$0.03$52.08 million$54.86 millionViewN/AView Earnings Details
11/3/2016Q316$0.02$0.07$55.97 million$55.20 millionViewN/AView Earnings Details
8/3/2016Q216$0.07$0.06$66.90 million$67.10 millionViewListenView Earnings Details
4/28/2016Q116$0.07$0.11$61.31 million$62.00 millionViewListenView Earnings Details
2/23/2016Q415$0.29$0.36$91.04 million$91.10 millionViewListenView Earnings Details
11/5/2015Q315$0.23$0.50$82.98 million$91.30 millionViewN/AView Earnings Details
8/6/2015Q215$0.21$0.16$74.06 million$77.60 millionViewN/AView Earnings Details
5/7/2015Q115$0.40$0.63$70.90 million$70.80 millionViewN/AView Earnings Details
3/3/2015Q414$0.44$0.53$63.50 million$66.50 millionViewN/AView Earnings Details
11/11/2014Q314$0.29$0.63$57.10 million$58.30 millionViewN/AView Earnings Details
8/12/2014Q214$0.30$0.48$52.77 million$55.70 millionViewN/AView Earnings Details
3/4/2014Q413$0.55$0.71$34.73 million$40.20 millionViewN/AView Earnings Details
11/12/2013Q3$0.33$0.58$27.00 million$29.20 millionViewListenView Earnings Details
8/13/2013Q213$0.12$0.35$15.07 million$18.80 millionViewN/AView Earnings Details
6/3/2013Q113$0.01$2.00 million$11.10 millionViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for Insys Therapeutics (NASDAQ:INSY)
Current Year EPS Consensus Estimate: $-0.48 EPS
Next Year EPS Consensus Estimate: $-0.16 EPS

Dividends

Dividend History for Insys Therapeutics (NASDAQ:INSY)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading and Institutional Ownership History for Insys Therapeutics (NASDAQ:INSY)
Insider Ownership Percentage: 69.20%
Institutional Ownership Percentage: 45.21%
Insider Trades by Quarter for Insys Therapeutics (NASDAQ:INSY)
Institutional Ownership by Quarter for Insys Therapeutics (NASDAQ:INSY)
Insider Trades by Quarter for Insys Therapeutics (NASDAQ:INSY)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
5/18/2017Steven J MeyerDirectorBuy8,000$12.21$97,680.00View SEC Filing  
5/16/2017Saeed MotahariCEOBuy4,500$11.98$53,910.00View SEC Filing  
11/4/2016Steven J MeyerDirectorBuy10,000$10.75$107,500.00View SEC Filing  
8/16/2016Theodore H StanleyDirectorSell15,000$18.02$270,300.00View SEC Filing  
8/12/2016John N Kapoor Trust Dated SeptMajor ShareholderBuy5,700$18.57$105,849.00View SEC Filing  
8/11/2016Patrick FourteauDirectorSell15,000$18.46$276,900.00View SEC Filing  
8/9/2016Daniel BrennanVPSell5,781$19.16$110,763.96View SEC Filing  
6/6/2016Theodore H StanleyDirectorSell16,000$16.27$260,320.00View SEC Filing  
5/12/2016John N Kapoor Trust Dated SeptMajor ShareholderBuy50,000$12.84$642,000.00View SEC Filing  
3/4/2016Patrick FourteauDirectorSell15,000$18.22$273,300.00View SEC Filing  
11/17/2015John N Kapoor Trust Dated SeptMajor ShareholderBuy5,000$29.50$147,500.00View SEC Filing  
11/12/2015John N Kapoor Trust Dated SeptMajor ShareholderBuy10,000$26.58$265,800.00View SEC Filing  
11/12/2015Patrick FourteauDirectorSell30,000$26.48$794,400.00View SEC Filing  
9/14/2015Theodore H. StanleyDirectorSell4,000$37.04$148,160.00View SEC Filing  
6/10/2015Fosse Franc DelGeneral CounselSell10,000$34.48$344,800.00View SEC Filing  
6/5/2015Steven J MeyerDirectorSell5,000$63.00$315,000.00View SEC Filing  
5/27/2015Brian TambiDirectorSell3,100$60.09$186,279.00View SEC Filing  
5/26/2015Brian TambiDirectorSell1,800$60.00$108,000.00View SEC Filing  
5/20/2015Patrick FourteauDirectorSell9,064$60.00$543,840.00View SEC Filing  
5/18/2015Darryl S BakerCFOSell10,000$59.17$591,700.00View SEC Filing  
5/11/2015Steven J MeyerDirectorSell18,000$57.06$1,027,080.00View SEC Filing  
3/17/2015Michael L BabichCEOSell75,000$58.63$4,397,250.00View SEC Filing  
3/11/2015Patrick FourteauDirectorSell10,000$59.94$599,400.00View SEC Filing  
3/10/2015Theodore H StanleyDirectorSell3,300$60.03$198,099.00View SEC Filing  
2/9/2015Darryl S BakerCFOSell30,000$52.23$1,566,900.00View SEC Filing  
11/19/2014Patrick FourteauDirectorSell25,000$39.11$977,750.00View SEC Filing  
11/4/2014Michael L BabichCEOSell80,000$38.66$3,092,800.00View SEC Filing  
8/13/2014Theodore H StanleyDirectorBuy3,000$33.93$101,790.00View SEC Filing  
6/16/2014John N KapoorDirectorBuy5,000$26.13$130,650.00View SEC Filing  
6/13/2014John N KapoorDirectorBuy5,000$25.44$127,200.00View SEC Filing  
6/12/2014John N KapoorDirectorBuy20,000$24.84$496,800.00View SEC Filing  
6/11/2014John N KapoorDirectorBuy20,000$24.54$490,800.00View SEC Filing  
5/19/2014Theodore StanleyDirectorBuy4,000$21.94$87,760.00View SEC Filing  
5/15/2014Patrick FourteauDirectorBuy7,500$22.77$170,775.00View SEC Filing  
3/5/2014Larry DillahaInsiderSell149,932$74.57$11,180,429.24View SEC Filing  
3/5/2014Michael BabichCEOSell288,432$74.58$21,511,258.56View SEC Filing  
1/16/2014Darryl BakerCFOSell10,000$49.61$496,100.00View SEC Filing  
1/15/2014Darryl BakerCFOSell10,000$47.54$475,400.00View SEC Filing  
1/14/2014Darryl BakerCFOSell10,000$45.64$456,400.00View SEC Filing  
12/9/2013John KapoorDirectorSell27,428$47.25$1,295,973.00View SEC Filing  
8/16/2013Michael BabichCEOBuy1,000$24.90$24,900.00View SEC Filing  
8/14/2013Patrick FourteauDirectorBuy5,000$23.77$118,850.00View SEC Filing  
6/4/2013Michael L BabichCEOBuy1,250$10.93$13,662.50View SEC Filing  
5/24/2013Pierre LapalmeDirectorBuy3,000$10.39$31,170.00View SEC Filing  
5/14/2013Patrick FourteauDirectorBuy5,000$10.90$54,500.00View SEC Filing  
5/13/2013Patrick FourteauDirectorBuy4,800$10.90$52,320.00View SEC Filing  
5/7/2013Patrick FourteauDirectorBuy50,000$8.36$418,000.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Headline Trends for Insys Therapeutics (NASDAQ:INSY)
Latest Headlines for Insys Therapeutics (NASDAQ:INSY)
Source:
DateHeadline
nasdaq.com logoInsys Therapeutics, Inc. Announces FDA Final Product Label for Syndros - Nasdaq
www.nasdaq.com - May 24 at 10:50 PM
reuters.com logoBRIEF-Insys Therapeutics announces FDA final product label for Syndros
www.reuters.com - May 24 at 11:32 AM
finance.yahoo.com logoInsys Therapeutics, Inc. Announces FDA Final Product Label for Syndros
finance.yahoo.com - May 24 at 11:32 AM
finance.yahoo.com logoCannabis' Impact on the Brain in This New Study Should Encourage Marijuana Stock Investors
finance.yahoo.com - May 21 at 8:44 AM
finance.yahoo.com logoMarijuana Stock Winners of the Week
finance.yahoo.com - May 20 at 5:44 PM
americanbankingnews.com logoSteven J. Meyer Acquires 8,000 Shares of Insys Therapeutics Inc (INSY) Stock
www.americanbankingnews.com - May 18 at 8:11 PM
globenewswire.com logoInsys Therapeutics Announces Chief Financial Officer Transition - GlobeNewswire (press release)
globenewswire.com - May 17 at 5:54 PM
reuters.com logoBRIEF-Insys Therapeutics announces chief financial officer transition
www.reuters.com - May 17 at 9:57 AM
americanbankingnews.com logoInsys Therapeutics Inc (INSY) CEO Saeed Motahari Purchases 4,500 Shares
www.americanbankingnews.com - May 16 at 10:17 PM
finance.yahoo.com logoBragar Eagel & Squire, P.C. Announces that a Class Action Lawsuit has been Filed against Insys Therapeutics, Inc. (INSY) and Encourages Investors to Contact the Firm
finance.yahoo.com - May 16 at 11:02 AM
finance.yahoo.com logoInsys Therapeutics Announces Chief Financial Officer Transition
finance.yahoo.com - May 16 at 11:02 AM
finance.yahoo.com logoFINAL DEADLINE ALERT - Bronstein, Gewirtz & Grossman, LLC Reminds Investors of Class Action Against INSYS Therapeutics, Inc. (INSY) and Lead Plaintiff Deadline - May 16, 2017
finance.yahoo.com - May 15 at 10:53 AM
americanbankingnews.com logoInsys Therapeutics Inc (INSY) Cut to "Neutral" at Piper Jaffray Companies
www.americanbankingnews.com - May 14 at 5:50 PM
finance.yahoo.com logoEdited Transcript of INSY earnings conference call or presentation 9-May-17 2:00pm GMT
finance.yahoo.com - May 14 at 5:48 PM
finance.yahoo.com logoUPCOMING DEADLINE: The Law Offices of Vincent Wong Reminds Investors of INSYS Therapeutics, Inc. of Commencement of a Class Action Lawsuit and a Lead Plaintiff Deadline of May 16, 2017 - INSY
finance.yahoo.com - May 12 at 6:41 PM
finance.yahoo.com logoThe Wagner Firm Reminds Investors of May 16th Deadline in the Class Action Lawsuit Against Insys Therapeutics, Inc.
finance.yahoo.com - May 12 at 6:41 PM
finance.yahoo.com logoSHAREHOLDER ALERT: Levi & Korsinsky, LLP Reminds Shareholders It Has Filed a Complaint in U.S. District Court to Recover Losses Suffered by Investors in INSYS Therapeutics, Inc.
finance.yahoo.com - May 11 at 11:35 PM
finance.yahoo.com logoINSYS Therapeutics, Inc. – Value Analysis (NASDAQ:INSY) : May 11, 2017
finance.yahoo.com - May 11 at 11:35 PM
businesswire.com logoMay 16 Deadline Alert: Law Offices of Howard G. Smith Reminds ... - Business Wire (press release)
www.businesswire.com - May 11 at 6:32 PM
finance.yahoo.com logoMay 16 Deadline Alert: Tostrud Law Group, P.C. Reminds Investors of Upcoming Deadline in the Class Action Lawsuit Against Insys Therapeutics, Inc.
finance.yahoo.com - May 11 at 6:32 PM
finance.yahoo.com logoEQUITY ALERT: Rosen Law Firm Announces Filing of Securities Class Action Lawsuit Against Insys Therapeutics, Inc. - INSY
finance.yahoo.com - May 11 at 6:32 PM
marketwatch.com logoMarijuana Stocks Drive Corporate Value by Delivering Automation, Technology and Diverse Application
www.marketwatch.com - May 10 at 6:20 PM
finance.yahoo.com logoINSYS Therapeutics, Inc. breached its 50 day moving average in a Bullish Manner : INSY-US : May 10, 2017
finance.yahoo.com - May 10 at 6:20 PM
finance.yahoo.com logoINSYS Therapeutics, Inc.: Gathering momentum, can it sustain its performance?
finance.yahoo.com - May 10 at 6:20 PM
finance.yahoo.com logoInvestors Are Betting Big Against Marijuana Stock Insys Therapeutics -- Why They're Wrong
finance.yahoo.com - May 10 at 6:20 PM
finance.yahoo.com logoINSY Investors: GPM Reminds Investors of the May 16 Deadline in the Class Action Lawsuit Against Insys Therapeutics, Inc.
finance.yahoo.com - May 10 at 6:20 PM
finance.yahoo.com logoHere's Why Marijuana Stock Insys Therapeutics Briefly Plunged As Much As 11%
finance.yahoo.com - May 10 at 6:20 PM
fool.com logoWhy Insys Therapeutics Inc. Jumped Higher Today - Motley Fool
www.fool.com - May 10 at 1:20 PM
finance.yahoo.com logoDEADLINE ALERT - Bronstein, Gewirtz & Grossman, LLC Reminds Investors of Class Action Against INSYS Therapeutics, Inc. (INSY) & Lead Plaintiff Deadline - May 16, 2017
finance.yahoo.com - May 10 at 1:19 PM
fool.com logoWhy Insys Therapeutics Inc. Jumped Higher Today
www.fool.com - May 9 at 4:58 PM
americanbankingnews.com logoInsys Therapeutics Inc (INSY) Announces Quarterly Earnings Results, Misses Estimates By $0.03 EPS
www.americanbankingnews.com - May 9 at 4:46 PM
finance.yahoo.com logoInvestor Network: Insys Therapeutics, Inc. to Host Earnings Call
finance.yahoo.com - May 9 at 12:22 PM
finance.yahoo.com logoMay 16 Deadline Alert: Law Offices of Howard G. Smith Reminds Insys Therapeutics, Inc. Investors of Upcoming Lead Plaintiff Deadline and Encourages Investors to Contact the Firm
finance.yahoo.com - May 9 at 12:22 PM
finance.yahoo.com logoInsys Therapeutics Reports First Quarter 2017 Results
finance.yahoo.com - May 9 at 12:22 PM
finance.yahoo.com logoInsys in talks with U.S. to resolve probe of opioid spray
finance.yahoo.com - May 9 at 12:22 PM
marketbeat.com logoInsys Therapeutics reports 1Q loss
marketbeat.com - May 9 at 10:50 AM
americanbankingnews.com logo$37.89 Million in Sales Expected for Insys Therapeutics Inc (INSY) This Quarter
www.americanbankingnews.com - May 9 at 12:58 AM
americanbankingnews.com logo-$0.09 Earnings Per Share Expected for Insys Therapeutics Inc (INSY) This Quarter
www.americanbankingnews.com - May 9 at 12:58 AM
finance.yahoo.com logoSHAREHOLDER ALERT: Levi & Korsinsky, LLP Reminds Shareholders It Has Filed in U.S. District Court to Recover Losses Suffered by Investors in INSYS Therapeutics, Inc.
finance.yahoo.com - May 8 at 5:37 PM
bizjournals.com logoResearch Reports Initiation on Biotech Stocks -- Trevena, Ocular Therapeutix, INSYS Therapeutics, and Pain Therapeutics
www.bizjournals.com - May 5 at 10:56 PM
globenewswire.com logoInsys Therapeutics, Inc. Appoints Rohit Vishnoi to Board of Directors - GlobeNewswire (press release)
globenewswire.com - May 5 at 5:56 PM
americanbankingnews.com logoZacks: Analysts Anticipate Insys Therapeutics Inc (INSY) Will Post Quarterly Sales of $37.89 Million
www.americanbankingnews.com - May 5 at 12:56 PM
nasdaq.com logoInsys Therapeutics, Inc. Appoints Rohit Vishnoi to Board of Directors - Nasdaq
www.nasdaq.com - May 4 at 6:07 PM
finance.yahoo.com logoInsys Therapeutics, Inc. Appoints Rohit Vishnoi to Board of Directors
finance.yahoo.com - May 4 at 6:07 PM
finance.yahoo.com logoDEADLINE ALERT - Bronstein, Gewirtz & Grossman, LLC Reminds Investors of Class Action Against INSYS ... - Yahoo Finance
finance.yahoo.com - May 4 at 8:28 AM
americanbankingnews.com logo-$0.09 EPS Expected for Insys Therapeutics Inc (INSY) This Quarter
www.americanbankingnews.com - May 4 at 1:31 AM
finance.yahoo.com logoDEADLINE ALERT - Bronstein, Gewirtz & Grossman, LLC Reminds Investors of Class Action Against INSYS Therapeutics, Inc. (INSY) and Lead Plaintiff Deadline - May 16, 2017
finance.yahoo.com - May 2 at 10:35 AM
finance.yahoo.com logoThe Klein Law Firm Reminds Investors of the Filing of a Class Action on Behalf of INSYS Therapeutics, Inc. Shareholders and a Lead Plaintiff Deadline of May 16, 2017
finance.yahoo.com - May 1 at 6:17 PM
finance.yahoo.com logoSHAREHOLDER ALERT:  Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in INSYS Therapeutics, Inc. of Class Action Lawsuit and Upcoming Deadline – INSY
finance.yahoo.com - April 30 at 9:15 AM
americanbankingnews.com logoInsys Therapeutics (INSY) Earns Coverage Optimism Rating of -0.05
www.americanbankingnews.com - April 29 at 3:33 PM

Social

Chart

Insys Therapeutics (INSY) Chart for Thursday, May, 25, 2017

This page was last updated on 5/25/2017 by MarketBeat.com Staff